# Index

## ABANDONMENT

Generally, **9:72 to 9:77** Circumstances, **9:72** Good faith reply, **9:73** Timely completion of application, **9:74** Timely payment of fees, **9:77** Timely payment of maintenance feeds, **9:75** Timely request for examination, **9:76** 

## **ACCOUNT OF PROFITS**

Generally, **14:47 to 14:59** Apportionment, **14:56** Condonation, **14:59** Expenses, **14:55** Indirect profits, **14:57** Interest, **14:58** Measure of profits, **14:49** differential cost approach, **14:51** differential profits approach, **14:52** full cost approach, **14:50** Multiple parties, **14:48** Proof of the expenses, **14:54** 

# AGENT

See PATENT AGENT

#### **APPLICATION FOR A PATENT**

Generally, 9:1 et seq. Additional term, 9:85.20 to 9:85.40 Applications filed before October 1, 1989 — "Old Act applications" amendments, 9:103 supplementary disclosure, 9:103 conflicting applications, 9:104 to 9:106 conflict exists, 9:104 federal court, 9:106 patent office, 9:105 due care, 9:78.50 examination. 9:102 priority date, 9:94 convention priority, 9:94 earliest corresponding foreign application, 9:94 foreign application, 9:94

© 2023 Thomson Reuters, Rel. 6, 12/2023

# **APPLICATION FOR A PATENT** -Cont'd Applications filed before October 1, 1989 - "Old Act applications"—Cont'd priority date, 9:94—Cont'd same invention, 9:94 significance of, 9:94 public inspection, not open to, 9:95 to **9:100** substances intended for food, 9:101 Applications filed on or after October 1, 1989 abandonment, 9:72 to 9:77 circumstances, 9:72 good faith reply, 9:73 timely completion of application, 9:74 timely payment of fees, 9:77 timely payment of maintenance fees, 9:75 timely request for examination, 9:76 allowance of an application, 9:83 amendments, 9:61 to 9:65 after allowance, 9:65 application, 9:61 include sequence listings, 9:63 limitation after rejection, 9:64 new matter, 9:62 appeal from decision of commissions, 9:86 to 9:90 appeal decisions, 9:90 appeal to federal court, 9:86 powers of the federal court, 9:89 procedure on appeals, 9:87 standard of review, 9:88 appeal to the patent appeal board, 9:82 application, 9:31 to 9:36 abstract, 9:33 petition, 9:32 specification, 9:34 appointment of patent agents, 9:22 appointment of representative, 9:23 claim date, 9:38 to 9:45 applicant, request for priority by, 9:44

# APPLICATION FOR A PATENT

-Cont'd Applications filed on or after October 1. 1989—Cont'd claim date, 9:38 to 9:45-Cont'd disclosure of subject matter, 9:42 filing date, 9:43 multiple priorities, effect of, 9:45 prior application, 9:41 prior Canadian application, 9:39 prior convention or Treaty application, 9:40 requirements, 9:38 completing the application, 9:52 conflicting applications, 9:81 corrections, 9:66 divisional applications, 9:68 examination, 9:57 to 9:60 accelerated examination, 9:58 prosecution of application, 9:59 request for examination, 9:57 timely response in good faith, 9:60 fees, 9:25 to 9:30 current status, 9:28 fees for "small entity" applicants, 9:26 to 9:28 legislative correction, 9:27 maintenance fees, 9:29 reduced fees, 9:26 filing date, 9:37 filing prior art, third party, 9:80 good faith, issues of, 9:69 to 9:71 granting patent, 9:67 grant of a patent, 9:84 inventor, application by, 9:9 inventor's legal representative, application by, 9:9 joint inventors and applications, 9:12 to 9:21 appeal from decision of commission, 9:18 changing inventors named in patent, 9:21 consequences of misnaming inventors, 9:20 effect of refusal, 9:13 joining persons, 9:15 joint applicant had no part in invention, 9:14 joint investors, ownership rights of, 9:19

# **APPLICATION FOR A PATENT**

-Cont'd Applications filed on or after October 1. 1989-Cont'd joint inventors and applications, 9:12 to 9:21—Cont'd power of commissioner, 9:16, 9:17 section 31 appeal, 9:18 judicial review, 9:91 misrepresentation, 9:79 postal services interruption relief, 9:92 publication of the application, 9:53 confidentiality period, 9:54 secret applications and patents, 9:56 significance of the publication date, 9:55 refusal to grant patents, 9:85 reinstatement, 9:78 requesting priority, 9:46 to 9:51 withdrawal of request, 9:47 third party filing. 9:80 time. 9:24 Commission of patents, 9:2 to 9:4 Patent agents, 9:5 new patent agent privilege, 9:5 solicitor-client privilege, 9:5 Patent office. 9:2 to 9:4 communications with the patent office, 9:4 manual of patent office practice (MOPOP), 9:3

#### BIOTECHNOLOGY

Generally, **3:40 to 3:45** Animals, **3:44** Higher life forms, **3:42** Inventions biochemical, **3:40** biological, **3:40** Lower life forms, **3:41** Plants, **3:45** 

## CLAIM DATE

Generally, **9:38 to 9:45** Applicant, request for priority by, **9:44** Disclosure of subject matter, **9:42** Filing date, **9:43** Multiple priorities, effect of, **9:45** Prior application, **9:41** Prior Canadian application, **9:39** 

CLAIM DATE—Cont'd Prior convention or Treaty application, 9:40 Requirements, 9:38 COLLEGE OF PATENT AGENTS AND TRADEMARK AGENTS Generally, 16:1 et seq. COMMON GENERAL KNOWLEDGE IN THE ART Construction of a patent consideration of the common general knowledge of a person skilled in the art, 8:15 Obviousness determination of obviousness, 4:46 to 4:56 relevance of the common general knowledge in the art, 4:37 The specification common general knowledge in the art re the specification, 7:6 What is the common general knowledge in the art, 4:38 CONSTRUCTION OF THE PATENT Generally, 8:1 et seq. Claims, types of, 8:48 to 8:52 "Jepson" claims, 8:51 "Markush" claims, 8:52 product by process claims, 8:49 product claims, 8:48 "Swiss Form" claims, 8:50 "for," 8:50 Consideration, 8:64 Experts, role of, 8:63 First duty of court, 8:1 interpretation, 8:1 General principles, 8:7 to 8:10 abstract, 8:9 approach, 8:7 description, role of, 8:8 drawings, role of, 8:8 function of the claims, 8:10 Historical developments, 8:4 to 8:6 Canadian rules, 8:6 rules prior to 1981, 8:4

-Cont'd Rules of construction. 8:11 to 8:37 claims language, 8:31 to 8:35 consideration of variants, 8:32 determination of essential elements. 8.34 essential elements, 8:33 purposive construction, 8:31 U.K. law. 8:35 consider whole claim, 8:28 construed as a whole, 8:20 plain and ambiguous language, 8:20 construed objectively, 8:21 construed to avoid unreasonable result, 8:27 context, 8:26 date of publication, 8:12 disclaimed. 8:37 extrinsic evidence. 8:22 factual matrix, 8:19 meaning of term, 8:19 interpretation, consistency in, 8:30 interpreted in its context, 8:26 language, interpretation of, 8:29 language of patent specification, 8:26 person of ordinary skill in the art, 8:13 to 8:18 application, 8:17 common general knowledge, 8:15 expert evidence, 8:16 person skilled in art. 8:14 separate claims, 8:14 purposive construction, 8:24 read fairly, 8:25 redraft, should not, 8:36 Specification, construction of, 8:38 to 8:47 Specification, issues concerning, 8:38 to 8:47 alternatives. 8:41 dependence claims, 8:43, 8:44 antecedent claims, 8:43 element, included or additional, 8:44 inventions, single or multiple, 8:40 new result or method, 8:39 new technology, 8:47 numerical limitations, 8:46 promise of patent --- old law, 8:38 reference numbers, 8:42

CONSTRUCTION OF THE PATENT

© 2023 Thomson Reuters, Rel. 6, 12/2023

U.K. rules, 8:5

Prior decision, 8:65

Issue of law, 8:2

# CONSTRUCTION OF THE PATENT

-Cont'd Specification, issues concerning, 8:38 to 8:47—Cont'd reference to another claim, 8:45 Terms, 8:53 to 8:62 "about," 8:53 "approximately," 8:54 "comprising," 8:55 "contain." 8:56 "for," 8:57 functional claims, 8:58 "obvious chemical equivalent," 8:59 pharmaceutical preparation, 8:60 relative terms, 8:62 "treatment," 8:61 Types of claims, 8:48 to 8:52 "Jepson" claims, 8:51 "Markush" claims, 8:52 product by process claims, 8:49 product claims, 8:48 "Swiss Form" claims, 8:50 Written instruments. 8:3 Interpretation Act, 8:3

# CORRECTION

Certificate of correction for clerical errors, 12:28 to 12:30 Correction by the court, 12:31

#### DAMAGES

Generally, 14:17 to 14:45 Absence of licences, 14:27 Aggravated damages, 14:45 Alternatives, 14:43 Damages from use, 14:28 Effect of licences, 14:26 Loss due to price reduction, 14:37 to 14:39 market disruption, 14:38 post infringement losses, 14:39 Loss of profit, 14:29 to 14:36 Lost sales, 14:29 to 14:36 Measure of damages, 14:18 Mitigation, 14:42 Plaintiff's loss, 14:19 Profits of infringer, 14:19 Reasonable royalty, 14:41 Recovery of plaintiff's damages, 14:44 Sales patentee, 14:40

#### **DEDICATION TO THE PUBLIC**

Generally, **12:40 to 12:42** Dedication, **12:40** Effect of dedication, **12:42** Reasons for dedication, **12:41** 

**DESCRIPTION OF INVENTION** Generally, 7:9 to 7:25 Clarity, 7:18 ambiguity. 7:19 definition of materials, 7:21 errors and inaccuracies, 7:20 proportions of ingredients, 7:22 Failure to meet disclosure requirements, 7:25 Good faith, 7:23 Misleading matter, 7:24 Nature of the invention, 7:10 Necessity for experiments, 7:16 Operation and use, 7:11 Reference to previous documents, 7:17 Standards for disclosure, 7:12 to 7:15 contemplated by the inventor, 7:13 general points, 7:12

# DISCLAIMER

Generally, **12:18 to 12:27** British authorities, **12:23** Effect, **12:27** Extent, **12:24** Form, **12:26** Function, **12:25** History Canada, **12:20** U.K., **12:18** U.S., **12:19** Statutory provisions for disclaimer, **12:21** United States authorities, **12:22** 

# DISCLOSURE

Generally, **5:1 et seq.** Applicant, **5:50** Filing date, **5:49 to 5:52** General considerations, **5:15** Infringe, **5:17** Patent or publication, disclosure by, **5:32 to 5:48** claimed subject matter, **5:43** construction, **5:36** directions, **5:43** drawing, **5:37** 

DISCLOSURE—Cont'd Patent or publication, disclosure by, 5:32 to 5:48-Cont'd enabling disclosure, 5:44 evidence of obviousness, 5:48 exact prior description, 5:42 experiments, 5:41 language, 5:35 no mosaic of documents, 5:34 oral disclosure, 5:38 paper anticipation, 5:47 photograph, 5:37 prior description, 5:32 public accessibility, 5:33 same invention, 5:39 similarity of language, 5:45 sufficiency of description, 5:40 use unnecessary. 5:46 Person skilled in the art, 5:18 Public, 5:12 to 5:14 art cited in the patent, 5:13 available to the public, 5:12 enabling disclosure, 5:14 Public use or sale, 5:22 to 5:31 accidental use, 5:31 analogous use, 5:25 enabling disclosure, 5:26 experimental use, 5:29 impractical device, 5:27 inoperable device, 5:27 method or result, **5:30** same invention, 5:24 secret use, 5:28 Same invention, 5:16 Without experimentation, 5:19 Without invention, 5:20 **DOUBLE PATENTING** 

Generally, 11:13 to 11:18

#### **EXAMINATION**

Generally, **9:57 to 9:60** Accelerated examination, **9:58** Prosecution of application, **9:59** Request for examination, **9:57** Timely response in good faith, **9:60** 

# **EXPERT EVIDENCE**

Expert evidence as to the prior art, **4:32** Expert evidence as to the qualities and capabilities of the person skilled in the art, **4:35** 

© 2023 Thomson Reuters, Rel. 6, 12/2023

EXPERT EVIDENCE—Cont'd Expert evidence to assist construction of the patent, 8:2, 8:16, 8:26 Proof of infringement, 13:14 FILING APPLICATIONS, OLD ACT Generally, 9:93 Benefit, 9:94 Conflicting applications, 9:104 to 9:106 conflict exists, 9:104 federal court, 9:106 patent office, 9:105 Convention priority, 9:94 Earliest corresponding foreign application, 9:94 Examination, 9:102 Foreign application, 9:94 No new matter, 9:103 Priority date, 9:94 significance of. 9:94 Public inspection, not open to, 9:95 to **9:10**0 Same invention, 9:94 Substances intended for food, 9:101 Supplementary disclosure, 9:103 **INFRINGEMENT** Generally, 13:1 et seq. Assignee, 13:69 Burden of proof, 13:8 Canada, must occur in. 13:47 Cause of action, 13:72 Constructing, 13:38 to 13:46 Construction of patent, 13:10 Construed infringement, 13:11 to 13:16 approach, 13:11 combinations, 13:13 common law, 13:16 intention, 13:12 new product, 13:15 presumption, 13:15 proof of infringement, 13:14 Crown right to use, 13:66 Exclusive right of patentee, 13:6 to 13:8 Expiry, effect of, 13:35 "Gillette defence," 13:17 Historical, 13:2, 13:3 Inducing infringement, 13:49 affiliated companies, 13:52 aiding and abetting, 13:54 common design, 13:53

#### **INFRINGEMENT—Cont'd**

Inducing infringement, 13:49-Cont'd good faith belief in invalidity, 13:49 supplying product, 13:50 vicarious liability, 13:55 Infringement by officers and directors, 13:56 Infringing Acts, 13:19 Liability for patent infringement, 13:67 Liability, partners, 13:55.50 Liability, partnerships, 13:55.50 Licensee, 13:70 Making, 13:38 to 13:46 Non-infringement defences, 13:57 to 13:65 experimental and developmental, 13:57 foreign vehicle entering Canada temporarily, 13:61 laches and acquiescence, 13:63 licence, 13:59 limitation period, 13:62 manufacture, 13:58 patent misuse, 13:64 use and sale, 13:60 Old Act patents, 13:4, 13:5 Patentee, 13:68 Patentee, persons claiming under, 13:71 Patent term, activity during, 13:20 to 13:37 articles acquired prior to filing, 13:21 to 13:28 correction. 13:32 dedication, 13:34 disclaimer, 13:31 re-examination. 13:33 reissue, 13:30 Purposive construction, 13:2 Selling, 13:38 to 13:46, 13:48 Statutory grant, 13:18 Three aspects of patent infringement, 13:7 U.K. law, 13:3 Using, 13:38 to 13:46, 13:48 **INTERNATIONAL PATENT** PROTECTION Generally, 10:1 et seq.

Canada-European Union, Comprehensive Economic and Trade Agreement (CETA), **10:20** North America Free Trade Agreement (NAFTA), **10:14** 

# **INTERNATIONAL PATENT PROTECTION**—Cont'd Paris convention. 10:2 Patent Cooperation Treaty (PCT), 10:3 amendment of the claims, 10:7 examination, 10:9 international application, 10:4 international publication, 10:8 international search, 10:5 national phase entry, 10:12, 10:13 right to practice, 10:10 third party observations, 10:6 time limits, 10:11 Patent Law Treaty (PLT), 10:18 Strasbourg Agreement, 10:19 Trade-Related aspects of Intellectual Property Rights (TRIPS), 10:15 TRIPS and patents, 10:16 TRIPS disputes, 10:17

#### **INVENTION**

Generally, **2:1 et seq.** Accidental discovery, **2:8** Date of invention, **2:10** Definition in Patent Act, **2:3** Discovery, **2:7** Idea, **2:6** Inventive ingenuity, **2:4** Inventor: CITE2:11 historical background, **2:12** Patent Act, **2:13** Making an invention, **2:9** Patent granted, **2:1** 

#### JOINT INVENTORS AND APPLICATIONS

Generally, **9:12 to 9:21** Appeal from decision of commission, **9:18** Appeal under section 31, **9:18** Changing inventors named in patent, **9:21** Consequences of misnaming inventors, **9:20** Effect of refusal, **9:13** Joining persons, **9:15** Joint applicant had no part in invention, **9:14** Joint investors, ownership rights of, **9:19** 

Power of commissioner, 9:16, 9:17

LICENSEE Right of action for patent infringement, 13:70 **MAINTENANCE FEES** Generally, 9:29, 11:20 NOVELTY Generally, 5:1 et seq. Anticipation of novelty, **5:2** Common general knowledge, 5:11 Consideration of novelty, 5:54 to 5:65 chemical product, 5:56 claims made by a particular process, 5:57 combinations, 5:54 confidential communications, 5:64 enantiomers, 5:60 new use, 5:58 novelty in part, 5:62 process, 5:55 product for a new use, 5:59 rediscovery, 5:63 selection patents, 5:61 Co-pending patent applications, section 28.2(1)(c),(d), 5:53 Description in patent or publication, 5:75 anticipation under sections 27(1)(b) and 28(2), 5:77 printed publication, 5:76 Development of requirements, 5:3, 5:4 Canadian laws, 5:4 U.K. laws. 5:3 Disclosure anticipate, 5:17 filing date, **5:49 to 5:52** applicant, 5:50 one year before filing date, 5:51 general considerations, 5:15 infringe, 5:17 Enablement, 5:21 Essential nature, 5:1 Evidence of novelty, 5:66 Lack of novelty, 5:2 Novelty applications, 5:80 Old Act, 5:67 Patent or publication, 5:32 to 5:48 claimed subject matter, 5:43 construction, 5:36 directions, 5:43 drawing, 5:37

**NOVELTY**—Cont'd Patent or publication, 5:32 to 5:48 -Cont'd enabling disclosure, 5:44 evidence of obviousness, 5:48 exact prior description, 5:42 experiments, 5:41 language, 5:35 no mosaic of documents, 5:34 oral disclosure, 5:38 paper anticipation, 5:47 person skilled in the art, 5:18 photograph, 5:37 prior description, 5:32 public accessibility. 5:33 same invention, 5:39 similarity of language, 5:45 sufficiency of description, 5:40 use unnecessary, 5:46 Person skilled in the art, 5:10 Prior foreign grant, section 27(2), 5:79 Prior to invention, knowledge or use, Old Act, 5:68 to 5:74 conflict, 5:73 disclosure to public before filing date, 5:72 invention date, 5:69 section 61, 5:71 section 61(3), 5:74 Public. 5:12 to 5:14 art cited in the patent, 5:13 available to the public, 5:12 enabling disclosure, 5:14 Public use or sale, 5:22 to 5:31 accidental use, 5:31 analogous use, 5:25 before filing date, 5:78 enabling disclosure, 5:26 experimental use, 5:29 impractical device, 5:27 inoperable device, 5:27 method or result, 5:30 same invention, **5:16**, **5:24** every essential element claimed, 5:24 secret use, 5:28 without experimentation, 5:19 without invention, 5:20 Relevant dates, 5:9 Requirement of novelty, 5:1

© 2023 Thomson Reuters, Rel. 6, 12/2023

#### NOVELTY—Cont'd

Statutory requirements, current Act, **5:6** Subject matter defined by claim, **5:8** Test for anticipation, **5:5** Beloit test, **5:5** 

# **OBVIOUSNESS**

Generally, 4:1 et seq. Age of the prior art, 4:27 Anticipation, **4:2** Application of test for, 4:72 to 4:84 Cited art. 4:23 Claim, 4:39 to 4:45 Climate in the art, 4:63 Combination of factors, 4:69 Combinations, 4:72 Commercial success, 4:65 Common general knowledge in art, 4:37, 4:38 relevance, 4:37 Composition, 4:82 Constructive date of invention, 4:14 Current Act information disclosed, 4:18, 4:19 Date of invention, 4:12 to 4:14 filing date, 4:14 Determination of, 4:46 to 4:56 directly and without difficulty, 4:50 relevant date, 4:54 Disclosure. 4:21 Effort required to achieve invention, 4:60 Expert evidence, prior art, 4:32 Factors for determining, 4:57 to 4:69 activities of others, 4:66 File record. relevance of. 4:70 File wrapper, relevance of, 4:70 Hindsight, caution concerning, 4:55 Idea, 4:80 Industry praise, 4:67 Information outside the field, 4:26 Invention. 4:48 inventive ingenuity, 4:48 Inventive concept, 4:39 to 4:44 general principles, 4:42 U.K. law, 4:40 Issues to consider, 4:21 to 4:31 Locating art, **4:30** Manner of making the invention, 4:59 Material, 4:81 Mechanical skill, 4:53

## **OBVIOUSNESS—Cont'd**

Meritorious awards, 4:67 Motive to find the solution, 4:58 New use for old product or process, 4:77 Non-obviousness requirement, 4:3 to 4:6 Canadian law, 4:6 U.K. law, 4:4 U.S. law, 4:5 Omission, 4:80 Overview, 4:1 Patent Act, section 28.3, 4:9 Patents, **4:68** Post-art, 4:25 Prior art expert evidence as to, 4:32 Old Act, 4:16 Patent Act. 4:17 to 4:20 Priority date, 4:14 Product for a new use, 4:78 Proof of actual date of invention, 4:13 Proportions, 4:81 Prosecution of patent application, 4:24 Ouestion of fact, 4:52 Recently disclosed technology, 4:75 Reception of invention, 4:66 Relevance of a diligent search, 4:29 Relevant art. 4:22 Relevant date for obviousness Old Act, 4:12 to 4:14 Patent Act section 28.3, 4:15 Selection, 4:79 broad class, 4:73 Shape, 4:81 Simplicity, 4:61 utility, 4:62 Size, 4:81 Skilled in the art, person, 4:33 to 4:36 identify the person, 4:33 notional person, 4:34 qualities and capabilities, 4:35 expert evidence as to, 4:36 admissibility of expert evidence, 4:36 other, 4:35 State of the art, 4:45 Statutory test for obviousness, 4:9, 4:10 Subject-matter defined by the claim, 4:11 Test for obviousness Current Act, 4:9, 4:10 Old Act, 4:7, 4:8

**OBVIOUSNESS**—Cont'd Tests concerning prior art, 4:31 repitition, 4:31 PATENT AGENT College of Patent and Trademark Agents, 16:1 et seq. Patent Agents, 9:5 Appointment of Patent Agents, 9:23 Patent Agent Privilege, 9:8 Representation by a Patent Agent, 9:6 Retainer of a Patent Agent, 9:7 PATENT GRANT AND VALIDITY OF PATENTS Generally, 11:1 et seq. Conditions. 11:19 Double patenting, 11:13 to 11:18 Evidence, relevant, 11:9 to 11:12 commercial success. 11:12 proof of patents, 11:10 record file, 11:11 Grant. 11:1 Grant subject to adjudication, 11:4 Grounds of invalidity, 11:8 Invalid claims, 11:7 Maintenance feeds, 11:20 Marking of patented articles, **11:21 to** 11:24 benefit, 11:22 Canadian law. 11:21 false representations, 11:24 offences for false marking, 11:23 Nature of a challenge, **11:6** Nature of the grant, **11:2** Presumption of validity, 11:5 Prior grant, 11:13 to 11:18 Term of the grant, **11:3** PATENTS Generally, 1:1 et seq. Certificate of Supplementary Protection, 1:55 English law, **1:6 to 1:12** book of bounty, 1:9 British patents Acts, 1:12 law courts, 1:7

Obtaining by application, 1:4 Patent Act, 1:5, 1:13 to 1:28 history, 1:29 to 1:53 since 1989, 1:29 to 1:42 transition provisions, 1:43 to 1:53 which Patent Act applies, 1:43 to 1:53 Patented Medicines (Notice of Compliance) Regulations, 1:56 Patented Medicines Process Review Board, 1:57 Patented Medicines Regulation, 1:55 Patent Rules, 1:54 Purpose, 1:2 Statute of Monopolies, 1:58 PERSON SKILLED IN THE ART Construction of a patent consideration of the understanding of a person skilled in the art, 8:1, 8:2, 8:13 to 8:18 appropriate approach, 8:16 meaning of technical terms, 8:26 purposive construction, 8:24 purposive construction, essential and non-essential elements, 8:31 to 8:35, 13:10 Double patenting, 11:14 Novelty construction of a written description, 5:34 disclosure as understood by a person skilled in the art, 5:18 enablement, 5:21, 5:44 interpretation of a photograph or drawing, 5:37 Obvious to a person skilled in the art disclosure as understood by a person skilled in the art, 4:21 information outside the field of the person skilled in the art, 4:26 test for obviousness, Current Act, 4:9, 4:10 test for obviousness, Old Act, 4:7, 4:8 The person skilled in the art a notional person, 4:34 expert evidence as to the qualities and capabilities of the person skilled in the art, 4:35 qualities and capabilities of the person skilled in the art, 4:35

PATENTS—Cont'd

© 2023 Thomson Reuters, Rel. 6, 12/2023

monopolies, 1:6

Monopoly, patent, 1:3

Jurisdiction, limited by, 1:4

patents. 1:6

Governed, 1:5

#### PERSON SKILLED IN THE ART ---Cont'd

The specification, **7:1 et seq.** patent specification addressed to persons skilled in the art, **7:5**, **7:6**, **7:9**, **7:11 to 7:16**, **7:18**, **7:37**, **7:39 to 7:44** Utility construction of a promise of utility,

6:10 sound prediction of utility, 6:15 utility as specified when put into practice by a competent person, 6:9

#### PRIVILEGE

Patent Agent Privilege, **9:8** Privilege in Dealing with College of Patent Agents and Trademark Agents, **16:51** Privilege in Threats Action, **15:32** 

#### **RE-EXAMINATION**

Generally, **12:32 to 12:39** Advantages, **12:39** Disadvantages, **12:39** Question of patentability, **12:35** Re-examination proceeding, **12:36** Request, **12:33** 

## REISSUE

Generally, 12:1 to 12:17 Accident. 12:11 Application for reissue, 12:14 Deemed, 12:7 Defective, 12:8 Effect of reissue, 12:15 Error, **12:10** History Canada, 12:3 U.K., 12:1 U.S., 12:2 Inadvertence, 12:11 Inoperative, 12:8 Invalid patent, 12:9 Jurisdiction of commission, 12:6 Litigation involving reissued patent infringement of reissued patent, 12:16 validity of reissue, 12:17 Mistake, 12:11 No new matter, 12:13 Purpose and nature, 12:5

# **REISSUE—Cont'd**

Same invention, **12:12** Statutory provisions, **12:4** Valid patent, **12:9** 

## REMEDIES

Generally, 14:1 et seq. Account of profits, 14:47 to 14:59 apportionment, 14:56 condonation, 14:59 expenses, 14:55 indirect profits, 14:57 interest, 14:58 measure of profits, 14:49 differential cost approach, 14:51 differential profits approach, 14:52 full cost approach, 14:50 multiple plaintiffs, 14:48 proof of the expenses, 14:54 Appeals, 14:75 Claims of particular parties, 14:7 to 14:9 licensee, 14:8 parent for, 14:9 patentee, 14:7 Compensation for damages, 14:46 Compensatory remedies, 14:3 Costs, 14:6 Currency conversion, 14:64 Damages, 14:17 to 14:45 absence of licences, 14:27 alternatives. 14:43 damages from use, 14:28 effect of licences, 14:26 infringer's profits, 14:19 loss due to price reduction, 14:37 to 14:39 market disruption, 14:38 post infringement losses, 14:39 loss of profit, 14:29 to 14:36 lost sales, 14:29 to 14:36 measure of damages, 14:18 mitigation, 14:42 plaintiff's loss, 14:19 reasonable royalty, 14:41 recovery of plaintiff's damages, 14:44 relevance of a non-infringing alternative, 14:20 to 14:25 lost profits on lost sales, 14:21 Apotex v. Merck, 14:23

**REMEDIES**—Cont'd Damages, 14:17 to 14:45-Cont'd relevance of a non-infringing alternative. 14:20 to 14:25-Cont'd lost profits on lost sales, 14:21 -Cont'd pre-2015 Canadian jurisprudence, 14:22 reasonable royalty, 14:25 sale of non-infringing alternative, 14:24 sales patentee, 14:40 Declaration, 14:4, 14:68 Destruction on oath, 14:67 Effect of income tax, 14:65 Election of Damages or Account of Profits, 14:10 to 14:16 choosing the remedy, 14:15 damages and account of profits compared, **14:11** causation, 14:12 damages, 14:13 discretion of court, 14:14 Exemplary damages, 14:60 Injunction. 14:66 Interest, 14:61 post-judgment interest, 14:63 prejudgment interest, 14:62 preventive remedies, 14:2 Procedural considerations, 14:69 to 14:75 asserting a claim as to other types of alleged infringement, 14:72 compensation phase, 14:71 effect of judgment in a subsequent case revoking the patent, 14:73 liability judgment, 14:70 Punitive damages, 14:60 Punitive remedies, 14:5

#### SPECIFICATION

Generally, **7:1 et seq.** Claims, **7:36 to 7:44** broader than the invention, **7:40** general principle, **7:39** clarity of language, **7:37** definition of the ambit of the monopoly, **7:38** nature and function of the claims, **7:36** Common general knowledge in the art, **7:6** 

© 2023 Thomson Reuters, Rel. 6, 12/2023

SPECIFICATION—Cont'd Construction of, see SPECIFICATION, CONSTRUCTION OF Description of invention, 7:9 to 7:25 clarity, 7:18 ambiguity, 7:19 definition of materials, 7:21 errors and inaccuracies, 7:20 proportions of ingredients, 7:22 failure to meet disclosure requirements, 7:25 good faith, **7:23** misleading matter, 7:24 nature of the invention, 7:10 necessity for experiments, 7:16 operation and use. 7:11 reference to previous documents, 7:17 disclosure, 7:11 standards for disclosure, 7:12 to 7:15 contemplated by the inventor, 7:13 general points, 7:12 Description requirements in specific situations, 7:26 to 7:34 biological material, 7:32 description of known matter, 7:26 distinction between old and new matter, 7:33 matter necessarily implied, 7:27 principle, 7:34 selection patents, 7:31 size or shape, 7:28 sound prediction of utility, 7:30 utility, 7:29 Drawings, 7:35 Historical, 7:2, 7:3 development in the U.K., 7:2 evolution of Canadian laws, 7:3 Person skilled in the art, 7:5 Relevant date, 7:7 Statutory provisions, 7:4 SPECIFICATION, CONSTRUCTION OF Generally, 8:38 to 8:47 Alternatives, 8:41 Dependence claims, 8:43, 8:44

antecedent claims, **8:43** element, included or additional, **8:44** Inventions, single or multiple, **8:40** New result or method, **8:39** New technology, **8:47** 

# SPECIFICATION, CONSTRUCTION

OF—Cont'd Numerical limitations, 8:46 Promise of patent —- old law, 8:38 Reference numbers, 8:42 Reference to another claim, 8:45

## SUBJECT-MATTER OF PATENTS

Generally, 3:1 et seq. Biotechnology. 3:40 to 3:45 animals, 3:44 higher life forms, 3:42 biochemical inventions, 3:40 biological inventions, 3:40 lower life forms, 3:41 plants, 3:45 Business methods, 3:48 Business plans, 3:48 Business systems, 3:48 Combinations, 3:17 to 3:22 aggregation, 3:19 arrangement of parts, 3:22 common result essential, 3:18 novelty of elements, 3:20 omission and addition, 3:21 Computer programs, 3:46 Copyright, 3:53 Data processing systems, 3:46 Definitions, 3:9 to 3:14 art. 3:10 composition of matter, 3:14 machine, 3:12 manufacture. 3:13 process, 3:11 Development of requirements, 3:5 to 3:8 Canadian requirements, 3:8 U.K. requirements, 3:6 U.S. requirements, 3:7 Improvements, 3:50 Industrial designs, 3:52 Integrated circuit topographies, 3:54 Inventions dangerous, 3:57 ethically questionable, 3:57 immoral objects, 3:57 Mathematical formulas, other, 3:47 Patentability of claimed subject-matter, 3:4 Patentable subject-matter, 3:2

#### SUBJECT-MATTER OF PATENTS —Cont'd

Principles and theorems, 3:15, 3:16 knowledge of scientific principle, 3:16 patentability, 3:15 Process, 3:23 to 3:35 addition, 3:25 analogous purposes, 3:27 biological, 3:28 chemical. 3:28 general statement, 3:23 medical treatment of animals, 3:33 mental steps, 3:29 methods of medical treatment, 3:31 methods of surgical treatment, 3:31 new result, 3:24 non-medical treatment, 3:32 old result, 3:24 omission, 3:25 professional skills, 3:30 variation, 3:25 Products and substances, 3:36 to 3:39 food. 3:38 medicine, 3:38 non-obviousness, 3:37 novelty, 3:37 signals, 3:39 utility, 3:37 Selection, 3:49 Statutory provisions, 3:3 Trade-marks, 3:55 Unpatentable matter, 3:51

#### THREATS OF PATENT INFTRINGEMENT

Actions for Threats of Patent Infringement, 15:1 et seq.
Civil Code of Quebec, 15:15
Common Law Action for Trade Libel or Injurious Falsehood, 15:9 to 15:14
Competition Act, ss. 52 and 36, 15:31
Consumer Protection Legislation, 15:32
Patent Act, ss. 76.2 and 76.3, 15:33
Trademarks Act, s. 7(a), 15:16 to 15:30

# TRADEMARK AGENT College of Patent Agents and Trademark Agents, 16:1 et seq.

## UTILITY

Generally, **6:1 et seq.** As described and claimed, **6:3** inutility, **6:3** Assessed at filing date, **6:4** As specified, **6:9** Claim inutility, **6:16** broad class, **6:18** not useful products or processes, **6:17** omits an essential element, **6:19** Dangerous result or disadvantages, **6:7** Evidence as to utility, **6:22 to 6:24** commercial success, **6:24** infringement, **6:23** Filing date, **6:13** demonstrated utility, **6:14** 

# UTILITY—Cont'd Filing date, 6:13—Cont'd sound prediction of utility, 6:15 Historical, 6:2 Immoral objects, 6:8 Improvement patents, 6:20 invalidity, 6:13 In part, 6:12 Promised results, 6:10 Quantum, 6:6 Selection patents, 6:21 Statements of advantages, 6:11

#### VALIDITY OF PATENTS

See PATENT GRANT AND VALIDITY OF PATENTS